



COMPANY FACT SHEET

OVERVIEW

- Stabilitech is a privately owned biotechnology company, based in the Imperial College Incubator in central London, UK.
- Founded in 2002, Stabilitech initiated research activities in late 2004, with first significant funding in 2007.
- The company's research is focused on new technologies to stabilise vaccines, biopharmaceuticals and other biological products, removing the need for refrigeration

MARKET NEED

- Current vaccines require continuous storage and transport in a cold chain to ensure potency and safety. The elimination of the cold chain for vaccines, with reduced costs and – more importantly - protected efficacy for vaccination, is an important objective for public health. This has been explicitly identified by the Global Alliance for Vaccines and Immunization (GAVI) and other organisations.
- Biopharmaceuticals such as proteins are playing an increasingly important role in clinical practice and in pharmaceutical and biotechnology companies' portfolios. Almost all of these biopharmaceuticals currently also require refrigeration.

STABILITECH TECHNOLOGY

- Stabilitech's technology enables the long term thermo-stable storage of vaccines and other biological products through the addition of carefully selected excipients at optimised concentrations and ratios, followed by freeze drying. The technology has been successfully applied to enveloped and non-enveloped viruses, including both live and inactivated viruses, and also to biopharmaceuticals such as proteins, peptides, antibodies and enzymes.
- Stabilisation procedures are robust, and can readily be integrated into validated cGMP production processes, utilising current processing and freeze drying equipment.
- Typical excipients have been previously used in a clinical setting, are approved injectables, or have Generally Regarded As Safe (GRAS) status, with a relatively low cost of goods.

MANAGEMENT TEAM

- Dr Barbara Domayne-Hayman, CEO, was previously Commercial Director at Arrow Therapeutics, through to its acquisition by AstraZeneca in 2007. She has a broad commercial background from prior senior positions at Celltech, Ernst & Young, and Zeneca.
- Dr Jeff Drew, Founder and Chief Scientific Officer, has considerable experience in molecular virology, having worked at the Universities of Oxford and London and the Institute for Cancer Research. He is also founder and non-executive director of Cells4Life.
- Dr Stephen Ward, Development Director, was previously Director of Development at Onyvox, and brings considerable experience of immunology, vaccine development, manufacturing and regulatory aspects.

COMPANY CONTACT:

Dr Barbara Domayne-Hayman, CEO, Stabilitech Limited,
Imperial Incubator, Bessemer Building Level 1,
Imperial College London, South Kensington,
London SW7 2AZ, UK
Tel: +44 (0)20 7594 6146 Fax: +44 (0)20 7594 6119
bdh@stabilitech.com www.stabilitech.com